Welcome, Guest. Please login or register.
December 02, 2024, 05:43:09 am

Login with username, password and session length


Members
  • Total Members: 37984
  • Latest: Joe213
Stats
  • Total Posts: 775356
  • Total Topics: 66588
  • Online Today: 394
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 3
Guests: 336
Total: 339

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: PURPOSE Phase 3 preliminary study results - Injectable PrEP  (Read 3358 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 23,165
  • Threads: @jim16309
    • Social Media: Threads
POZ.com:

https://www.poz.com/article/nih-statement-preliminary-efficacy-results-twiceyearly-lenacapavir-hiv-prevention-cisgender-women

&

https://www.poz.com/article/twiceyearly-lenacapavir-prep-prevents-hiv-women

Quote
The injectable antiretroviral drug lenacapavir was safe and 100% effective as long-acting HIV pre-exposure prophylaxis (PrEP) among cisgender women in a Phase 3 clinical trial, according to top-line findings released by Gilead Sciences, Inc., the study sponsor.  Lenacapavir is administered every six months, making it the most durable HIV prevention method to have shown efficacy in this population.

NIAID applauds the study sponsor, investigators, study staff, and—most importantly—the participants in South Africa and Uganda, for contributing to this scientific advance for cisgender women, a population for whom biomedical HIV prevention evidence has been limited to date. We look forward to the release of additional data from this pivotal study, as well as the outcomes of companion studies of lenacapavir in other populations, to inform regulatory decisions on this novel PrEP method.

This study was mentioned in passing whilst discussing the CAPELLA trial in 2021 https://forums.poz.com/index.php?topic=75017.msg
« Last Edit: June 27, 2024, 10:48:02 am by Jim Allen »
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram
Threads

Offline Matts

  • Member
  • Posts: 273
Re: PURPOSE Phase 3 preliminary study results - Injectable PrEP
« Reply #1 on: July 24, 2024, 05:24:01 am »
I read some articles that Lenacapavir injectables "maybe could end HIV" and so on...
Maybe if it will be available worldwide for a cheap price...
We will see what will happen int he future when phase III results will be available.

A statement from UNAIDS I wanted to post:
"GENEVA, 10 July 2024— UNAIDS has welcomed the release of Gilead Sciences’ trial results on the injectable long-acting HIV medicine Lenacapavir for HIV prevention. The result “provides hope of accelerating efforts to end AIDS”, UNAIDS says, “but only if Gilead ensures that all people who need it can have access to this game-changing medicine....

“The success of Gilead’s recent Lenacapavir trial is an exciting development. While we still await regulatory approvals, normative guidance and results from the other ongoing trials, this news offers hope that we can enable everyone who would benefit, including especially the most marginalised communities, to have access to the help they need. Enabling equitable global access to new technologies can help get the world on track to end AIDS as a public health threat by 2030,” said Winnie Byanyima, Executive Director of UNAIDS. "However, it is concerning that Gilead’s latest announcement seems to mention neither upper-middle income countries, where people cannot afford anything like Lenacapavir’s current $42,250 price tag, nor a commitment to work with the UN-backed Medicines Patent Pool. Without these safeguards, it cannot be assured that this game-changing medicine will reach all those who need"

https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2024/july/20240710_lenacapavir
Dovato

 


Terms of Membership for these forums
 

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.